Tarantula toxin may yield non-opioid treatments for chronic pain

By Gareth Macdonald contact

- Last updated on GMT

iStock/HansLagerweij
iStock/HansLagerweij
A tarantula venom toxin that inhibits a novel pain receptor will guide development of more effective non-opioid painkillers say researchers in Australia.

The University of Queensland team made the claim at a Biophysical Society meeting this week after presenting data showing the toxin - ProTx-II – is attracted to nerve cells in such an orientation that it can inhibit a pain receptor called Nav1.7.

Understanding this interaction may aid drug design says researcher Sonia Troeira Henriques, who told us compounds based on ProTx-II that can block Nav1.7 could be used to treat patients who have developed resistance to opioid painkillers. 

At this stage we can’t guarantee that ProTx-II will be pursued as a painkiller, but the fact that inhibits receptors distinct from opioid receptors, is of potential therapeutic interest as it might bring alternatives to the current drugs​.”

ProTx-II is found in the venom of the Peruvian green velvet tarantula (Thrixopelma pruriens​). An earlier study​ suggested it could block the transmission of pain, however, prior to Henriques’ work the interaction was poorly understood.

We are interested in the three-dimensional structure and in characterizing the mode-of-action of this toxin​” she said, explaining that the ProTx-II being studied by her team is synthesized chemically rather than being extracted from tarantula venom.

Currently we produce it chemically, but we are also making progresses in expressing it recombinantely using bacterial expression​” Henriques said, adding that “at this stage we can’t be sure which way will be best to obtain the peptide toxin in greater amounts​.”

ProTx-II may never bused therapeutically but a better understanding its mode of action “will help the design of painkillers that can target Nav1.7 in an efficient and selective manner and with fewer side effects than current drugs on the market​” Henriques said.

Related topics: Bio Developments, Cell lines

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Related suppliers

Follow us

Products

View more

Webinars